As of February 1,
2008, we have more than 35 partnerships with pharmaceutical and
biotechnology companies to jointly develop and commercialize products or
to enable other companies to use our UltiMAb technology in their
development and commercialization of new therapeutic products. While we have collaborations involving co-promotion and in-licensing agreements, in general, our partnerships fall into two major categories: (1) collaborative partnerships in
which we collaborate with partners to jointly generate, develop and commercialize human antibody products; and (2) out-licensing partnerships in which we license our human antibody generation technology to our partners in exchange for license fees, milestone payments, and royalties.
Our 50/50 Collaborative Partnerships
Our UltiMAb Out-Licensing Partnerships
|
